Generic Name: copanlisib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Aliqopa is a PI3K kinase inhibitor approved for relapsed follicular lymphoma.
Aliqopa inhibits phosphatidylinositol-3-kinase (PI3K), an enzyme that is part of signaling pathways that play a role in cell growth and metabolism. It has strong activity against forms of PI3K that are present on cancerous B cells, which grow out of control in people with leukemia and lymphoma.
Aliqopa received accelerated approval based on promising response rates in a clinical trial.
Aliqopa is administered as an intravenous infusion given once weekly in cycles of three weeks on and one week off treatment.
Common side effects include diarrhea, nausea, weakness and lower respiratory tract infections. It can cause depletion of white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potentially serious side effects include high blood sugar (hyperglycemia), high blood pressure and lung inflammation (pneumonitis).
For More Info: https://www.hcp.aliqopa-us.com/
Co-Pay Program Info: https://www.hcp.aliqopa-us.com/access-and-reimbursement/arc-program/
Patient Assistance Program Info: https://www.hcp.aliqopa-us.com/access-and-reimbursement/arc-program/
Last Reviewed: September 21, 2018